Your browser doesn't support javascript.
loading
Trichotillomania Treatment Update. / Actualización en el tratamiento de la tricotilomanía.
Nina Dominguez, L; Imbernón-Moya, A; Saceda-Corralo, D; Vano-Galván, S.
Afiliação
  • Nina Dominguez L; Servicio de Dermatología, Instituto Dermatológico Dominicano y Cirugía de Piel «Dr. Huberto Bogaert Díaz¼, Santo Domingo, República Dominicana. Electronic address: lauranina55@gmail.com.
  • Imbernón-Moya A; Servicio de Dermatología, Hospital Universitario Severo Ochoa, Madrid, Spain; Trichology Unit, Grupo de Dermatología Pedro Jaén, Madrid, España.
  • Saceda-Corralo D; Trichology Unit, Grupo de Dermatología Pedro Jaén, Madrid, España; Servicio de Dermatología, Hospital Universitario Ramón y Cajal, Departamento de Biología de Sistemas, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, España.
  • Vano-Galván S; Trichology Unit, Grupo de Dermatología Pedro Jaén, Madrid, España; Servicio de Dermatología, Hospital Universitario Ramón y Cajal, Departamento de Biología de Sistemas, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, España.
Actas Dermosifiliogr ; 2024 May 18.
Article em En, Es | MEDLINE | ID: mdl-38768806
ABSTRACT
Trichotillomania (TTM) is an obsessive-compulsive disorder in which affected individuals recurrently pull-out hair from any region of the body, causing hair loss or alopecia. The management of TTM is a therapeutic challenge for dermatologists and consists of a combination of pharmacological and non-pharmacological alternatives. Cognitive-behavioral therapy has successfully been used to treat TTM. However, not all patients are willing to follow this treatment strategy. Unconventional support tools are proposed, such as electronic devices, internet therapies and microneedling. N-acetylcysteine and memantine are considered suitable first-line therapies thanks to their favorable safety and efficacy profile, low risk of adverse effects, and significant benefits. The use of other drugs, including fluoxetine, clomipramine, olanzapine, and naltrexone has limited evidence of variable efficacy. The present review illustrates the current treatment modalities for the management of TTM.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En / Es Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En / Es Ano de publicação: 2024 Tipo de documento: Article